| hyp-SDA-2026-04-08-g | ADCY8-PKA-CREB Spatial Memory Enhancement | 0.46 | 0.50 | ADCY8 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| hyp-SDA-2026-04-08-g | Ribosomal Stress Response Exploitation | 0.46 | 0.50 | LTN1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Cytoskeletal Transport Selectivity Enhancement | 0.46 | 0.50 | KIF5A | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Membrane Lipid Composition Therapeutic Modulation | 0.46 | 0.50 | HMGCR | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Phase Separation Modulation Therapy | 0.46 | 0.50 | FUS | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Chaperone Network Reprogramming Therapy | 0.46 | 0.50 | HSPA1A | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Mitochondrial Proteostasis Coupling Therapy | 0.46 | 0.50 | ATF5 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Lysosomal pH Gradient Manipulation | 0.46 | 0.50 | ATP6V1A | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| hyp-SDA-2026-04-08-g | Dual SPI1 Inhibition for Atherosclerosis-Neurodegeneration Axis | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Epigenetic SPI1 Reprogramming Therapy | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | SPI1-C1Q Transcriptional Circuit Drives Cerebrovascular Neuroinflammation | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Neurovascular Unit SPI1 Signaling Hub | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Microglial SPI1 Priming by Circulating C1Q | 0.46 | 0.50 | C1Q | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Temporal SPI1 Inhibition for Neuroplasticity Recovery | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | SPI1-Mediated Metabolic Reprogramming in Neuroinflammation | 0.46 | 0.50 | SPI1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| hyp-SDA-2026-04-08-g | Oligodendrocyte Stress Response Uniformity | 0.46 | 0.50 | EIF2AK3 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Iron Dysregulation as Convergent Pathomechanism | 0.46 | 0.50 | GPX4 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Cord Microglia Activation State Convergence | 0.46 | 0.50 | CX3CR1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Cord Astrocyte Reactivity Convergence | 0.46 | 0.50 | STAT3 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Spinal Vascular Unit Breakdown as Universal Driver | 0.46 | 0.50 | VEGFA | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Sphingosine-1-Phosphate Gradient Disruption | 0.46 | 0.50 | S1PR1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Complement Cascade as Final Common Effector | 0.46 | 0.50 | C5AR1 | active | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| hyp-SDA-2026-04-08-g | Glymphatic System Disruption | 0.46 | 0.50 | AQP4 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Temporal Window Specificity | 0.46 | 0.50 | TNF | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | CNS-Peripheral Cytokine Compartmentalization | 0.46 | 0.50 | LRP1 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Astrocyte-Neuron Metabolic Coupling | 0.46 | 0.50 | SLC16A7 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Microglial State-Dependent Cytokine Function | 0.46 | 0.50 | TREM2 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Synaptic Plasticity Preservation | 0.46 | 0.50 | TNFRSF1B | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Compensatory Cytokine Network Activation | 0.46 | 0.50 | NLRP3 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| hyp-SDA-2026-04-08-g | Sphingolipid Metabolism Rebalancing | 0.46 | 0.50 | SMPD1 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Lactate Shuttle Pathway Enhancement | 0.46 | 0.50 | SLC16A1 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Mitochondrial Contact Site Stabilization | 0.46 | 0.50 | VDAC1 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Purinergic-Metabolic Coupling Restoration | 0.46 | 0.50 | P2RY12 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Lipid Droplet Dynamics as Therapeutic Lever | 0.46 | 0.50 | DGAT1 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis | 0.46 | 0.50 | MTOR | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | NAD+ Salvage Pathway Optimization | 0.46 | 0.50 | NAMPT | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| hyp-SDA-2026-04-08-g | Light-Independent Chronopharmacology | 0.46 | 0.50 | CSNK1D/CSNK1E | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Microglial-Specific Circadian Gene Therapy | 0.46 | 0.50 | ARNTL | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Clock Gene-Mediated Microglial Reprogramming | 0.46 | 0.50 | ARNTL/CLOCK | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Circadian Extracellular Matrix Remodeling | 0.46 | 0.50 | MMP9/HAS2 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | REV-ERB Agonist Microglial Deactivation | 0.46 | 0.50 | NR1D1/NR1D2 | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Circadian Metabolic Reprogramming Therapy | 0.46 | 0.50 | SIRT1/PRKAA1/PPARGC1A | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-08-g | Temporal Cytokine Receptor Modulation | 0.46 | 0.50 | IL1R1/TNFRSF1A | active | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| hyp-SDA-2026-04-04-f | Synaptic Vesicle Protein Phosphorylation Reprograms Release Probability and Inte | 0.46 | 0.50 | SYN1 (Synapsin-1) | active | 2026-04-28 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-SDA-2026-04-04-f | Synaptic Mitochondrial Proteostasis Collapse Disrupts ATP-Demand Coupling at Act | 0.46 | 0.50 | PPID (Cyclophilin D) | active | 2026-04-28 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-SDA-2026-04-04-f | Cdk5/p25-PSD-95 Phosphorylation Disrupts Synaptic Scaffolding and Shifts APP Pro | 0.46 | 0.50 | PSD-95 (DLG4) | active | 2026-04-28 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| hyp-sda-2026-04-01-g | RNA Granule Phase Separation as Transient Cross-Seeding Hub | 0.46 | 0.50 | TARDBP | active | 2026-04-28 | sda-2026-04-01-gap-9137255b |
| hyp-sda-2026-04-01-g | Membrane Lipid Composition-Dependent Specificity Switch Enabling Cross-Seeding R | 0.46 | 0.50 | PLD3 | active | 2026-04-28 | sda-2026-04-01-gap-9137255b |
| hyp-sda-2026-04-01-g | Galectin-3 as Damage-Sensor Scaffold for Multimeric Cross-Seeding at Compromised | 0.46 | 0.50 | LGALS3 | active | 2026-04-28 | sda-2026-04-01-gap-9137255b |
| h-ae924ee8 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuron | 0.46 | 0.50 | C1QA/C1QB/C1QC | proposed | 2026-04-15 | SDA-2026-04-15-gap-pubmed-20260411-082509-118fcb37 |